Targeting Cancer with CRISPR/Cas9-Based Therapy
Cancer is a devastating condition characterised by the uncontrolled division of cells with many forms remaining resistant to current treatment. A hallmark of cancer is the gradual accumulation of somatic mutations which drive tumorigenesis in cancerous cells, creating a mutation landscape distinctiv...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/1/573 |
| _version_ | 1797498644942815232 |
|---|---|
| author | Katarzyna Balon Adam Sheriff Joanna Jacków Łukasz Łaczmański |
| author_facet | Katarzyna Balon Adam Sheriff Joanna Jacków Łukasz Łaczmański |
| author_sort | Katarzyna Balon |
| collection | DOAJ |
| description | Cancer is a devastating condition characterised by the uncontrolled division of cells with many forms remaining resistant to current treatment. A hallmark of cancer is the gradual accumulation of somatic mutations which drive tumorigenesis in cancerous cells, creating a mutation landscape distinctive to a cancer type, an individual patient or even a single tumour lesion. Gene editing with CRISPR/Cas9-based tools now enables the precise and permanent targeting of mutations and offers an opportunity to harness this technology to target oncogenic mutations. However, the development of safe and effective gene editing therapies for cancer relies on careful design to spare normal cells and avoid introducing other mutations. This article aims to describe recent advancements in cancer-selective treatments based on the CRISPR/Cas9 system, especially focusing on strategies for targeted delivery of the CRISPR/Cas9 machinery to affected cells, controlling Cas9 expression in tissues of interest and disrupting cancer-specific genes to result in selective death of malignant cells. |
| first_indexed | 2024-03-10T03:36:17Z |
| format | Article |
| id | doaj.art-06888ee6c37d4bdeadaf7f71e3a72388 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T03:36:17Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-06888ee6c37d4bdeadaf7f71e3a723882023-11-23T11:42:03ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-01-0123157310.3390/ijms23010573Targeting Cancer with CRISPR/Cas9-Based TherapyKatarzyna Balon0Adam Sheriff1Joanna Jacków2Łukasz Łaczmański3Laboratory of Genomics & Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, PolandFaculty of Life Sciences and Medicine, Guy’s Campus, King’s College London, London SE1 9RT, UKSt. John’s Institute of Dermatology, Guy’s Campus, King’s College London, London SE1 9RT, UKLaboratory of Genomics & Bioinformatics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, PolandCancer is a devastating condition characterised by the uncontrolled division of cells with many forms remaining resistant to current treatment. A hallmark of cancer is the gradual accumulation of somatic mutations which drive tumorigenesis in cancerous cells, creating a mutation landscape distinctive to a cancer type, an individual patient or even a single tumour lesion. Gene editing with CRISPR/Cas9-based tools now enables the precise and permanent targeting of mutations and offers an opportunity to harness this technology to target oncogenic mutations. However, the development of safe and effective gene editing therapies for cancer relies on careful design to spare normal cells and avoid introducing other mutations. This article aims to describe recent advancements in cancer-selective treatments based on the CRISPR/Cas9 system, especially focusing on strategies for targeted delivery of the CRISPR/Cas9 machinery to affected cells, controlling Cas9 expression in tissues of interest and disrupting cancer-specific genes to result in selective death of malignant cells.https://www.mdpi.com/1422-0067/23/1/573cancergenetic therapyCRISPR/Cas9targeting |
| spellingShingle | Katarzyna Balon Adam Sheriff Joanna Jacków Łukasz Łaczmański Targeting Cancer with CRISPR/Cas9-Based Therapy International Journal of Molecular Sciences cancer genetic therapy CRISPR/Cas9 targeting |
| title | Targeting Cancer with CRISPR/Cas9-Based Therapy |
| title_full | Targeting Cancer with CRISPR/Cas9-Based Therapy |
| title_fullStr | Targeting Cancer with CRISPR/Cas9-Based Therapy |
| title_full_unstemmed | Targeting Cancer with CRISPR/Cas9-Based Therapy |
| title_short | Targeting Cancer with CRISPR/Cas9-Based Therapy |
| title_sort | targeting cancer with crispr cas9 based therapy |
| topic | cancer genetic therapy CRISPR/Cas9 targeting |
| url | https://www.mdpi.com/1422-0067/23/1/573 |
| work_keys_str_mv | AT katarzynabalon targetingcancerwithcrisprcas9basedtherapy AT adamsheriff targetingcancerwithcrisprcas9basedtherapy AT joannajackow targetingcancerwithcrisprcas9basedtherapy AT łukaszłaczmanski targetingcancerwithcrisprcas9basedtherapy |